Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
- Market Cap ₹ 8.40 Cr.
- Current Price ₹ 2.10
- High / Low ₹ 3.95 / 1.90
- Stock P/E
- Book Value ₹ 1.12
- Dividend Yield 0.00 %
- ROCE -3.76 %
- ROE -16.0 %
- Face Value ₹ 1.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -20.8% over past five years.
- Promoter holding is low: 20.0%
- Company has a low return on equity of 1.46% over last 3 years.
- Company has high debtors of 927 days.
- Promoter holding has decreased over last 3 years: -27.8%
- Working capital days have increased from 132 days to 277 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 3.46 | 6.44 | 2.22 | 9.37 | 9.22 | 9.14 | 14.21 | 14.41 | 2.91 | 62.48 | |
| 0.05 | 0.05 | 0.06 | 3.63 | 5.80 | 2.25 | 9.66 | 9.09 | 9.07 | 13.48 | 13.60 | 3.27 | 62.67 | |
| Operating Profit | -0.05 | -0.05 | -0.06 | -0.17 | 0.64 | -0.03 | -0.29 | 0.13 | 0.07 | 0.73 | 0.81 | -0.36 | -0.19 |
| OPM % | -4.91% | 9.94% | -1.35% | -3.09% | 1.41% | 0.77% | 5.14% | 5.62% | -12.37% | -0.30% | |||
| 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.53 | 0.50 | 0.83 | 0.39 | 0.05 | 0.03 | 0.06 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.42 | 0.35 | 0.30 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Profit before tax | -0.05 | -0.05 | -0.06 | -0.16 | 0.27 | -0.45 | -0.20 | 0.15 | 0.46 | 0.69 | 0.43 | -0.69 | -0.43 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 11.11% | 0.00% | 0.00% | 33.33% | 0.00% | 17.39% | 25.58% | 0.00% | |
| -0.05 | -0.05 | -0.06 | -0.16 | 0.24 | -0.45 | -0.20 | 0.10 | 0.46 | 0.57 | 0.32 | -0.70 | -0.45 | |
| EPS in Rs | -0.01 | -0.01 | -0.32 | -0.04 | 0.06 | -0.11 | -0.05 | 0.02 | 0.12 | 0.14 | 0.08 | -0.18 | -0.11 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -21% |
| 3 Years: | -32% |
| TTM: | 714% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1225% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -24% |
| 3 Years: | -47% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 4% |
| 3 Years: | 1% |
| Last Year: | -16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.76 | 3.76 | 0.19 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Reserves | -3.54 | -3.59 | -0.16 | -0.32 | -0.08 | -0.53 | -0.73 | -0.63 | -0.17 | 0.40 | 0.72 | 0.02 | 0.50 |
| 0.39 | 0.48 | 0.50 | 0.53 | 0.77 | 0.90 | 0.18 | 0.18 | 4.42 | 6.56 | 3.26 | 6.09 | 7.29 | |
| 0.08 | 0.09 | 0.11 | 2.72 | 4.96 | 6.46 | 8.83 | 4.38 | 5.96 | 9.48 | 8.89 | 3.80 | 33.34 | |
| Total Liabilities | 0.69 | 0.74 | 0.64 | 6.93 | 9.65 | 10.83 | 12.28 | 7.93 | 14.21 | 20.44 | 16.87 | 13.91 | 45.13 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.03 | 0.02 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 |
| 0.69 | 0.74 | 0.64 | 5.02 | 7.74 | 8.92 | 10.37 | 6.01 | 12.30 | 18.53 | 14.93 | 11.98 | 43.21 | |
| Total Assets | 0.69 | 0.74 | 0.64 | 6.93 | 9.65 | 10.83 | 12.28 | 7.93 | 14.21 | 20.44 | 16.87 | 13.91 | 45.13 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.03 | -0.04 | -0.05 | -1.98 | -0.16 | 1.37 | 2.80 | -3.08 | -0.68 | 0.16 | 1.80 | -2.47 | |
| 0.00 | 0.00 | 0.00 | 1.90 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | -0.04 | -0.01 | |
| 0.03 | 0.09 | 0.02 | -2.28 | -0.53 | -1.38 | -2.58 | 2.80 | 0.65 | -0.08 | -1.77 | 2.44 | |
| Net Cash Flow | 0.00 | 0.05 | -0.02 | -2.36 | -0.69 | -0.01 | 0.22 | -0.30 | -0.03 | 0.09 | -0.01 | -0.04 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 266.89 | 287.35 | 910.86 | 249.70 | 241.88 | 293.52 | 312.86 | 262.67 | 926.92 | |||
| Inventory Days | 215.20 | 150.49 | 352.10 | 33.94 | 17.04 | 95.98 | 45.34 | 50.62 | 255.36 | |||
| Days Payable | 304.36 | 319.46 | 1,059.97 | 325.07 | 164.40 | 235.87 | 243.90 | 231.43 | 446.88 | |||
| Cash Conversion Cycle | 177.72 | 118.38 | 202.98 | -41.43 | 94.52 | 153.63 | 114.30 | 81.86 | 735.40 | |||
| Working Capital Days | 369.22 | 251.08 | 656.01 | 139.07 | 156.37 | 51.91 | 45.98 | 72.70 | 277.20 | |||
| ROCE % | -8.06% | -7.94% | -10.17% | -5.06% | 14.38% | -0.66% | 6.14% | 17.71% | 15.08% | 11.66% | 8.98% | -3.76% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - With Schedule III Part A Para A of SEBI (LODR) regulations, 2015, we enclose copies of the newspaper advertisments publisherd by the company on 12th …
- Reg. 34 (1) Annual Report. 4 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Copies of the postal ballot notice for seeking approval of members of the company, the amendementof the Object Clause of the Memorandum of Association (MOA) …
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
14 Nov - Postal ballot to approve MOA amendment adding plastic/polymer packaging business; e-voting Nov 17–Dec 16, 2025.
-
Results - Financial Results For 30Th September, 2025
14 Nov - Board approved MOA expansion into plastic packaging; postal ballot Nov17–Dec16; CS Chaitra Arora appointed; Q2 Sep30 results approved.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products